医学
心室辅助装置
内科学
重症监护室
心肌病
冠状动脉监护室
重症监护医学
心脏病学
儿科
急诊医学
心力衰竭
心肌梗塞
作者
Diana M. Torpoco Rivera,Anna Joong,Nikita D’Souza,Toni Duganiero,Angela Lorts,Joseph A. Spinner
出处
期刊:Asaio Journal
[Lippincott Williams & Wilkins]
日期:2023-10-20
卷期号:70 (2): 154-158
标识
DOI:10.1097/mat.0000000000002080
摘要
Adult patients on left ventricular assist device (LVAD) support have increased morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There are no reported clinical data describing outcomes among pediatric patients on ventricular assist device (VAD) support infected with SARS-CoV-2. We conducted a retrospective study using the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry to evaluate patient characteristics and clinical outcomes after SARS-CoV-2 infection. A total of 22 children on VAD support (median age at infection 10.6 years) from 16 centers tested positive for SARS-CoV-2. Cardiomyopathy (59.1%) and congenital heart disease (40.9%) were the most common primary diagnoses. The type of support included LVAD in 19 (86.4%), biventricular assist device (BIVAD) in one (4.5%), and single ventricle VAD in two (9%) patients. At the time of infection, 50% were outpatients, 23% were inpatients on a general cardiology floor, and 27% were in the cardiac intensive care unit (CICU). Most patients (82%) were symptomatic at time of diagnosis, but only 13% required escalation of respiratory support, and 31% received SARS-CoV-2 therapies. Notably, no mortality occurred, and significant morbidity was rare after SARS-CoV-2 infection in pediatric patients on VAD support.
科研通智能强力驱动
Strongly Powered by AbleSci AI